In August Kjell Alving, Professor at the Karolinska Institute, joined Aerocrine’s (STO:AEROB) management team responsible for scientific and medical affairs. Kjell Alving is one of the pioneers within the field of exhaled nitric oxide (NO) research and its clinical applications and has an extensive network within the international asthma community. In the early 1990s, Kjell was one of the researchers at the Karolinska Institute who discovered that exhaled NO was connected to lung inflammation. He found that people with asthma have higher levels of exhaled NO than healthy individuals. These discoveries led to the establishment of Aerocrine, of which Kjell is one of the founders. In 1990 he received a PhD in pharmacology at the Karolinska Institute. Since then, he has led a research group that, among other things, has focused on documenting the clinical use of exhaled NO in the treatment of asthma. Kjell will continue to work part-time as a professor at the Department of Women’s and Children’s Health at Uppsala University, but will spend most of his time at Aerocrine. “We are very pleased and proud that Kjell will now use his well-founded expertise and experience to support Aerocrine’s mission to expand the clinical use of exhaled NO for asthma care,” say Paul de Potocki, CEO of Aerocrine. “Kjell’s profound knowledge regarding exhaled NO and its role in asthma management will reinforce the likelihood of our success.”
